This is session 2 of the 2 part series: Improving the safe and effective use of DOACsRead more
Archive of: September, 2022
This is session 1 of the 2 part series: Improving the safe and effective use of DOACs.
Anticoagulants are linked to more deaths and severe harm than any other medicine, being involved in 2 out of 9 medicines related claims that end in damages. The DOACs are now the most popular anticoagulants, with almost 1 million patients in England taking these medicines. This number continues to grow on an annual basis. Whilst the DOACs require less frequent monitoring than older anticoagulants, it is essential that is still carried out, and in particular, renal function, as their dose needs to be optimised to CrCl. Recent national data has shown that 15% of patients taking DOACs in England may be on the wrong dose in relation to their renal function, putting them at an increased risk of harm.
In this first webinar of a 2-part series we will set the national safety context around the use of DOACs, in addition to what is happening that might influence this issue in England. We will also share current guidance on the appropriate dosing, monitoring and review of the DOACs.Read more
18-20 October 2022
Optimising prevention, management and outcomesRead more